Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes.

Ryan G, Briscoe TA, Jobe L.

Drug Des Devel Ther. 2009 Feb 6;2:203-14.

2.

Pramlintide in the treatment of type 1 and type 2 diabetes mellitus.

Ryan GJ, Jobe LJ, Martin R.

Clin Ther. 2005 Oct;27(10):1500-12. Review.

PMID:
16330288
3.

Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus.

Singh-Franco D, Robles G, Gazze D.

Clin Ther. 2007 Apr;29(4):535-62. Review.

PMID:
17617279
4.

Pramlintide: (AC 137, AC 0137, Symlin, Tripro-Amylin).

[No authors listed]

BioDrugs. 2003;17(1):73-9. Review.

PMID:
12534323
5.

Pramlintide for the treatment of diabetes mellitus.

Kleppinger EL, Vivian EM.

Ann Pharmacother. 2003 Jul-Aug;37(7-8):1082-9. Review.

PMID:
12841822
6.

Inhibition of glucagon secretion.

Young A.

Adv Pharmacol. 2005;52:151-71. Review.

PMID:
16492545
7.

Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control.

Weyer C, Maggs DG, Young AA, Kolterman OG.

Curr Pharm Des. 2001 Sep;7(14):1353-73. Review. Erratum in: Curr Pharm Des 2001 Dec;7(18):1967.

PMID:
11472273
8.

Role of Amylin in Type 1 and Type 2 Diabetes.

Hieronymus L, Griffin S.

Diabetes Educ. 2015 Dec;41(1 Suppl):47S-56S. doi: 10.1177/0145721715607642. Epub 2015 Sep 30. Review.

PMID:
26424675
9.

Pramlintide acetate.

McQueen J.

Am J Health Syst Pharm. 2005 Nov 15;62(22):2363-72. Review.

PMID:
16278328
10.

Managed care perspective on three new agents for type 2 diabetes.

VanDeKoppel S, Choe HM, Sweet BV.

J Manag Care Pharm. 2008 May;14(4):363-80. Review.

11.

The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus.

Fineman M, Weyer C, Maggs DG, Strobel S, Kolterman OG.

Horm Metab Res. 2002 Sep;34(9):504-8.

PMID:
12384827
12.

The role of pramlintide for weight loss.

Dunican KC, Adams NM, Desilets AR.

Ann Pharmacother. 2010 Mar;44(3):538-45. doi: 10.1345/aph.1M210. Epub 2010 Feb 17. Review.

PMID:
20164472
13.

The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes.

Fineman MS, Koda JE, Shen LZ, Strobel SA, Maggs DG, Weyer C, Kolterman OG.

Metabolism. 2002 May;51(5):636-41.

PMID:
11979398
14.

A review of exenatide as adjunctive therapy in patients with type 2 diabetes.

Robles GI, Singh-Franco D.

Drug Des Devel Ther. 2009 Sep 21;3:219-40.

15.

Pramlintide in the treatment of diabetes mellitus.

Edelman S, Maier H, Wilhelm K.

BioDrugs. 2008;22(6):375-86. doi: 10.2165/0063030-200822060-00004. Review.

PMID:
18998755
16.

Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus.

Iltz JL, Baker DE, Setter SM, Keith Campbell R.

Clin Ther. 2006 May;28(5):652-65. Review.

PMID:
16861088
17.
18.

Use of pramlintide: the patient's perspective.

Want L.

Diabetes Educ. 2006 May-Jun;32 Suppl 3:111S-118S.

PMID:
16751352
19.

Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes.

Ratner RE, Want LL, Fineman MS, Velte MJ, Ruggles JA, Gottlieb A, Weyer C, Kolterman OG.

Diabetes Technol Ther. 2002;4(1):51-61.

PMID:
12017421
20.

Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.

Weyer C, Gottlieb A, Kim DD, Lutz K, Schwartz S, Gutierrez M, Wang Y, Ruggles JA, Kolterman OG, Maggs DG.

Diabetes Care. 2003 Nov;26(11):3074-9.

PMID:
14578242

Supplemental Content

Support Center